Baseline predictors of virological response for chronic hepatitis B patients

World Journal of Gastroenterology

Volumn 15, Issue 34, 2009, Pages 4311-4315

  Wu, Xue Jie ^a   Wang, Yan ^a   Chen, Ji ^a   Wang, Gui Qiang ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Chronic hepatitis B; Hepatitis B virus; Peginterferon; Predictors; Virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIOTHYRONINE; PEGINTERFERON ALPHA2B; THYROTROPIN; THYROXINE; VIRUS DNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIGEN; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NONHUMAN; PREDICTION; SEROCONVERSION; SERODIAGNOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; BLOOD; DRUG EFFECT; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; POLYETHYLENE GLYCOLS;

EID: 70349570745     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4311     Document Type: Article

References (25)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745
2. Leemans WF, Janssen HL, de Man RA. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13: 2554-2567 (Pubitemid 46938824)
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539
4. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352
5. Sánchez-Tapias JM, Costa J, Mas A, Parés A, Bruguera M, Rodés J. Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B. J Hepatol 1988; 6: 15-22 (Pubitemid 18053325)
6. Yuen MF, Yuan HJ, Hui CK, Wong DK, Wong WM, Chan AO, Wong BC, Lai CL. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003; 52: 416-419
7. Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004; 3: 188-193
8. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705 (Pubitemid 46662938)
9. Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13: 4085-4090
10. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Jones EA. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325 (Pubitemid 18256902)
11. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763 (Pubitemid 19270158)
12. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295-301
13. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, Ma OC, Lauder IJ, Ng CP, Chung HT. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-2097
14. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002
15. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-650 (Pubitemid 34748154)
16. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-1430 (Pubitemid 35403533)
17. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129 (Pubitemid 40091801)
18. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAgpositive chronic hepatitis B. Hepatology 2008; 47: 428-434 (Pubitemid 351280710)
19. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157
20. Hodkinson CF, Simpson EE, Beattie JH, O'Connor JM, Campbell DJ, Strain JJ, Wallace JM. Preliminary evidence of immune function modulation by thyroid hormones in healthy men and women aged 55-70 years. J Endocrinol 2009; 202: 55-63
21. Chatterjee S, Chandel AS. Immunomodulatory role of thyroid hormones: in vivo effect of thyroid hormones on the blastogenic response of lymphoid tissues. Acta Endocrinol (Copenh) 1983; 103: 95-100
22. Fabris N, Mocchegiani E, Provinciali M. Pituitary-thyroid axis and immune system: a reciprocal neuroendocrineimmune interaction. Horm Res 1995; 43: 29-38
23. Barreiro Arcos ML, Gorelik G, Klecha A, Genaro AM, Cremaschi GA. Thyroid hormones increase inducible nitric oxide synthase gene expression downstream from PKC-zeta in murine tumor T lymphocytes. Am J Physiol Cell Physiol 2006; 291: C327-C336
24. Frick LR, Rapanelli M, Bussmann UA, Klecha AJ, Arcos ML, Genaro AM, Cremaschi GA. Involvement of thyroid hormones in the alterations of T-cell immunity and tumor progression induced by chronic stress. Biol Psychiatry 2009; 65: 935-942
25. El-Shaikh KA, Gabry MS, Othman GA. Recovery of agedependent immunological deterioration in old mice by thyroxine treatment. J Anim Physiol Anim Nutr (Berl) 2006; 90: 244-254